Jiangsu Hengrui Pharmaceuticals (01276): Fosrolapitant Palonosetron for Injection Receives Drug Registration Approval
Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received notice from the National Medical Products Administration approving a new indication for Fosrolapitant Palonosetron for Injection, the company's independently developed Class 1 innovative drug and China's first ultra-long-acting original dual-target antiemetic injection.
Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received a notice from the National Medical Products Administration approving a new indication for Fosrolapitant Palonosetron for Injection, the company's independently developed Class 1 innovative drug and China's first ultra-long-acting original dual-target antiemetic injection.
Fosrolapitant Palonosetron for Injection was approved for marketing in May 2025 for the prevention of acute and delayed nausea and vomiting induced by highly emetogenic chemotherapy (HEC) in adult patients.
Fosrolapitant Palonosetron for Injection is a combination formulation that simultaneously antagonizes the NK-1 receptor and the 5-HT3 receptor to suppress the vomiting reflex through dual pathways, offering differentiated advantages including high solubility, a favorable safety profile, and long-acting efficacy. Leveraging its ultra-long half-life of nearly 8 days, the product requires only one administration per chemotherapy cycle to simultaneously cover the acute, delayed, and super-delayed phases of CINV. According to available information, the comparable NK-1 receptor/5-HT3 receptor antagonist combination products already marketed overseas are Helsinn Healthcare's AKYNZEO intravenous formulation (fosnetupitant/palonosetron) and oral capsule formulation (netupitant/palonosetron), both of which have already been launched in China. As of now, the cumulative R&D investment in the Fosrolapitant Palonosetron for Injection-related projects is approximately RMB259.5 million (unaudited).
Related Articles

Shanying International Holdings (600567.SH): The actual controller's share increase plan is extended.

JXR (01951) repurchased 2.1895 million shares on November 19 for HK$4.855 million.

NAYUKI (02150) repurchased 2.39 million shares on November 19 for approximately HK$1.5719 million.
Shanying International Holdings (600567.SH): The actual controller's share increase plan is extended.

JXR (01951) repurchased 2.1895 million shares on November 19 for HK$4.855 million.

NAYUKI (02150) repurchased 2.39 million shares on November 19 for approximately HK$1.5719 million.






